2019 American Transplant Congress
Evaluating Potentially Inappropriate Prescribing in Older Kidney Transplant Recipients
*Purpose: While the Beers criteria (BC) and STOPP criteria (SC) have been validated in several patient populations to reduce medication use leading to adverse drug…2019 American Transplant Congress
Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus
*Purpose: Extended-release tacrolimus (Envarsus XR®, LCP-Tac) was approved in 2015 as conversion from tacrolimus immediate-release (Tac-IR) as part of the maintenance immunosuppression regiment post-kidney transplant.…2019 American Transplant Congress
Early Readmission After Renal Transplant As A Valuable Quality Measure
1Surgery, Rhode Island Hospital, Providence, RI, 2Nephrology, Rhode Island Hospital, Providence, RI
*Purpose: Patient and graft survival have been criticized as imprecise measures of transplant program quality. Thirty-day (30d) readmission rates, available nationally and attainable locally, may…2019 American Transplant Congress
Functional Measures of Frailty and Not Sarcopenia Predict Mortality in a Prospective Cohort of Liver Transplant Candidates
Division of Liver Diseases and Transplantation, Columbia Univeristy Medical Center, New York, NY
*Purpose: Sarcopenia determined by single slice measures of abdominal imaging have been correlated with liver transplant (LT) outcomes. However, in end-stage liver disease (ESLD), these…2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…2019 American Transplant Congress
Pneumocystis Prophylaxis in Solid Organ Transplant Recipients at Two Large Transplant Centers from 2015-2016: Why Not Trimethoprim-Sulfamethoxazole?
*Purpose: Trimethoprim-sulfamethoxazole (T/S) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis (ppx) after solid organ transplant (SOT). Perceived side effects may lead…2019 American Transplant Congress
Renal Function between Tenofovir and Entecavir in Post-Liver Transplanted Hepatitis B Patients
Transplantation, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Tenofovir, Nucleotide analogue polymerase inhibitor is already accepted as effective and tolerable drug for treatment of hepatitis B virus (HBV) as much as entecavir.…2019 American Transplant Congress
Cholecystitis in High-Acuity Patients Undergoing Liver Transplantation: A Five-Year Analysis of Incidence, Causes and Impact
Dumont-UCLA Liver Transplant Center, Department of Surgery, UCLA School of Medicine, Los Angeles, CA
*Purpose: While the incidence of gallbladder pathology is well described in the general population, there is almost no data on cholecystitis in liver transplant candidates…2019 American Transplant Congress
Safety and Efficacy of Peri-Operative Sublingual Tacrolimus in Pancreas Transplant as Compared to Oral Tacrolimus
*Purpose: Early post-transplant, use of oral or enteral medications in pancreas transplant (PTX) is difficult due to NG tubes put to suction. The use of…2019 American Transplant Congress
Metabolomic Study Of Sarcopenia In Patients Prior To Liver Transplantation
1Surgery, Indiana University, Indianapolis, IN, 2University of Washington, Seattle, WA
*Purpose: Sarcopenia is defined as the loss of muscle mass, typically associated with aging, but frequently appearing in liver disease patients. In particular, sarcopenia present…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 18
- Next Page »